In vivo evaluation in rodents of [123I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT2A receptor

Nuclear Medicine and Biology

Volumn 35, Issue 8, 2008, Pages 861-867

  Blanckaert, Peter B M ^a   Burvenich, Ingrid ^a   Wyffels, Leonie ^a   De Bruyne, Sylvie ^a   Moerman, Lieselotte ^a   De Vos, Filip ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

5 HT2A receptor; Brain tracer; P glycoprotein; Serotonin

Indexed keywords

(4 FLUOROPHENYL)[1 (3 IODOPHENETHYL)PIPERIDIN 4 YL]METHANONE I 123; CYCLOSPORIN A; GLYCOPROTEIN P; KETANSERIN; RADIOLIGAND; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG UPTAKE; IMAGING SYSTEM; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN FUNCTION; RADIOACTIVITY; RAT; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; CYCLOSPORINE; IODINE RADIOISOTOPES; KETANSERIN; MALE; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 56249109118     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.09.004     Document Type: Article

References (23)

1. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
2. Audenaert K., Van Laere K., Dumont F., Slegers G., et al. Decreased frontal serotonin 5-HT2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med 28 (2001) 175-182
3. Audenaert K., Van Laere K., Dumont F., Vervaet M., et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 44 (2003) 163-169
4. Hashimoto T., Kitamura N., Kajimoto Y., Shirai Y., et al. Differential changes in serotonin 5-Ht(1A) and 5-Ht(2) receptor-binding in patients with chronic-schizophrenia. Psychopharmacology 112 (1993) S35-S39
5. Meyer J.H., Kapur S., Houle S., DaSilva J., et al. Prefrontal cortex 5-HT2 receptors in depression: an [F-18]setoperone PET imaging study. Am J Psychiatry 156 (1999) 1029-1034
6. Mintun M.A., Sheline Y.I., Moerlein S.M., Vlassenko A.G., et al. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 55 (2004) 217-224
7. Peremans K., Audenaert K., Blanckaert P., Jacobs F., et al. Effects of aging on brain perfusion and serotonin-2A receptor binding in the normal canine brain measured with single photon emission tomography. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1393-1404
8. Peremans K., Audenaert K., Coopman F., Blanckaert P., et al. Estimates of regional cerebral blood flow and 5-HT2A receptor density in impulsive, aggressive dogs with Tc-99m-ECD and I-123-5-I-R91150. Eur J Nucl Med Mol Imaging 30 (2003) 1538-1546
9. Peremans K., Audenaert K., Hoybergs Y., Otte A., et al. The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with I-123-5-I-R91150 SPECT. Eur J Nucl Med Mol Imaging 32 (2005) 708-716
10. Halldin C., Lundkvist C., Ginovart N., Nyberg S., et al. [C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with PET. J Nucl Med 37 (1996) 424
11. Marner L., Knudsen G.M., Madsen K., Haugbol S., et al. Longitudinal assessment of cerebral 5-HT2A receptors in normal volunteers. An [18F]-altanserin PET study. Neuroimage 31 (2006) T101
12. Ngan E.T.C., Yatham L.N., Ruth T.J., and Liddle P.F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [F-18]setoperone. Am J Psychiatry 157 (2000) 1016-1018
13. Catafau A.M., Danus M., Bullich S., Llop J., et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: Part 1 - pseudoequilibrium interval and quantification methods. J Nucl Med 47 (2006) 919-928
14. Catafau A.M., Danus M., Bullich S., Nucci G., et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: Part 2 - ketanserin displacement. J Nucl Med 47 (2006) 929-937
15. Fu X., Tan P.Z., Kula N.S., Baldessarini R., et al. Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. J Med Chem 45 (2002) 2319-2324
16. Blanckaert P., Burvenich I., Devos F., and Slegers G. Synthesis and in vivo evaluation in mice of (I-123)-(4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) methanone as a potential SPECT-tracer for the serotonin 5-HT2A receptor. J Label Compounds Radiopharm 50 (2007) 183-188
17. Hendrikse N.H., Franssen E.J., Van der Graaf W.T.A., Vaalburg W., et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med 26 (1999) 283-293
18. Elsinga P.H., Hendrikse N.H., Bart J., van Waarde A., et al. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 7 (2005) 37-44
19. Ishiwata K., Kawamura K., Yanai K., and Hendrikse N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48 (2007) 81-87
20. Kiyono Y., Yamashita T., Doi H., Kuge Y., et al. Is MIBG a substrate of P-glycoprotein?. Eur J Nucl Med Mol Imaging 34 (2007) 448-452
21. Marian T., Szabo G., Goda K., Nagy H., et al. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging 30 (2003) 1147-1154
22. de Vries E.F.J., Kortekaas R., van Waarde A., Dijkstra D., et al. Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET tracer for P-glycoprotein. J Nucl Med 46 (2005) 1384-1392
23. Liow J.S., Lu S.Y., McCarron J.A., Hong J.S., et al. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [C-11](R)-(-)-RWAY. Synapse 61 (2007) 96-105